Biotech News
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
ir.replimune.com2026-05-06 14:54 EST
WOBURN, Mass. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a